Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jan 5;12:811291. doi: 10.3389/fgene.2021.811291

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Stasik, Mende, Schuster, Mahler, Aust, Tannapfel, Reinacher-Schick, Baretton, Krippendorf, Bornhäuser, Ehninger, Folprecht and Thiede.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Rapid prospective evaluation of ctDNA persistence in stage II CRC. (A) Time bar showing intervals of blood sampling, pathological analysis of primary tumor material, and ctDNA analysis post-tumor resection of stage II CRC patients (n = 67). Box plots represent median values with interquartile range; Box–Whiskers represent min. to max. values. (B) Molecular marker (and frequency) used for ctDNA analysis and samples positive for ctDNA (red). (C) NGS results of all ctDNA targets analyzed (n = 104) and corresponding false-positive rates (black) of individual mutations. Bars represent the sequencing coverage of each sample. ctDNA positive samples are presented in red.